Format

Send to

Choose Destination
Biochem Pharmacol. 2014 May 1;89(1):1-11. doi: 10.1016/j.bcp.2014.01.029. Epub 2014 Jan 31.

Merging old and new perspectives on nicotinic acetylcholine receptors.

Author information

1
Department of Pharmacology and Therapeutics, University of Florida, College of Medicine, PO Box 100267, 1200 Newell Drive, Gainesville, FL 32610-0267, USA. Electronic address: rlpapke@ufl.edu.

Abstract

This review covers history underlying the discovery of the molecular mediators of nicotine's effects in the brain and the diversity of the nicotinic acetylcholine receptor (nAChR) subtypes. Models are presented for both their structure and their function as mediators of signal transduction, with special consideration of the differences between the two main subtypes: heteromeric receptors, which are specialized for rapid electrochemical signal transduction, and homomeric α7 receptors, which have come to be implicated in both ionotropic and metabotropic signaling. This review presents perspectives on the pharmacology and therapeutic targeting of nAChRs for the treatment of nicotine dependence or disease.

KEYWORDS:

Allosteric proteins; Electrophysiology; Molecular biology; Signal transduction; Synaptic function

PMID:
24486571
PMCID:
PMC4755309
DOI:
10.1016/j.bcp.2014.01.029
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for Elsevier Science Icon for PubMed Central
Loading ...
Support Center